Michael Burkes Brophy Sells 2,415 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 2,415 shares of Natera stock in a transaction on Tuesday, October 28th. The stock was sold at an average price of $191.16, for a total value of $461,651.40. Following the transaction, the chief financial officer owned 65,993 shares in the company, valued at approximately $12,615,221.88. This represents a 3.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, October 29th, Michael Burkes Brophy sold 1,867 shares of Natera stock. The stock was sold at an average price of $190.64, for a total value of $355,924.88.
• On Monday, October 27th, Michael Burkes Brophy sold 781 shares of Natera stock. The stock was sold at an average price of $192.32, for a total value of $150,201.92.
• On Friday, October 24th, Michael Burkes Brophy sold 755 shares of Natera stock. The stock was sold at an average price of $196.77, for a total value of $148,561.35.
• On Thursday, October 23rd, Michael Burkes Brophy sold 495 shares of Natera stock. The stock was sold at an average price of $187.16, for a total value of $92,644.20.
• On Wednesday, October 22nd, Michael Burkes Brophy sold 920 shares of Natera stock. The shares were sold at an average price of $186.68, for a total transaction of $171,745.60.
• On Tuesday, October 21st, Michael Burkes Brophy sold 602 shares of Natera stock. The shares were sold at an average price of $187.95, for a total transaction of $113,145.90.
• On Tuesday, September 30th, Michael Burkes Brophy sold 2,491 shares of Natera stock. The shares were sold at an average price of $162.05, for a total transaction of $403,666.55.

Natera Trading Up 0.2%

Shares of NTRA opened at $193.22 on Friday. The firm has a market cap of $26.52 billion, a P/E ratio of -101.16 and a beta of 1.74. Natera, Inc. has a 12-month low of $120.67 and a 12-month high of $198.99. The company’s 50-day moving average price is $173.77 and its 200 day moving average price is $161.57.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The company had revenue of $546.60 million during the quarter, compared to analysts’ expectations of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The firm’s quarterly revenue was up 32.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. Equities research analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Institutional Trading of Natera

Institutional investors and hedge funds have recently bought and sold shares of the business. Bank of Jackson Hole Trust purchased a new stake in Natera during the first quarter worth about $29,000. TCTC Holdings LLC grew its position in shares of Natera by 114.8% during the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock worth $33,000 after buying an additional 124 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its position in shares of Natera by 83.5% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock worth $33,000 after buying an additional 106 shares in the last quarter. Hilltop National Bank acquired a new position in shares of Natera during the second quarter worth about $33,000. Finally, Oliver Lagore Vanvalin Investment Group acquired a new position in shares of Natera during the second quarter worth about $36,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently issued reports on NTRA shares. Piper Sandler restated an “overweight” rating and issued a $220.00 price objective (up from $210.00) on shares of Natera in a report on Monday, August 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a research note on Wednesday, October 8th. BNP Paribas raised Natera to a “hold” rating and set a $172.00 target price on the stock in a research note on Monday. BNP Paribas Exane upgraded shares of Natera from an “underperform” rating to a “neutral” rating and set a $172.00 price target on the stock in a research note on Monday. Finally, Barclays reiterated an “overweight” rating and set a $210.00 price target (up from $190.00) on shares of Natera in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $194.89.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.